Last update 01 Nov 2024

Cipaglucosidase alfa

Overview

Basic Info

Drug Type
Enzyme
Synonyms
Cipaglucosidase alfa (USAN), Cipaglucosidase alfa-ATGA
+ [1]
Target
Mechanism
Alpha glucosidase replacements
Inactive Indication-
Originator Organization
Inactive Organization-
Drug Highest PhaseApproved
First Approval Date
RegulationOrphan Drug (US)
Login to view timeline

External Link

KEGGWikiATCDrug Bank
D11798---

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Glycogen Storage Disease Type II
NO
20 Mar 2023
Glycogen Storage Disease Type II
EU
20 Mar 2023
Glycogen Storage Disease Type II
LI
20 Mar 2023
Glycogen Storage Disease Type II
IS
20 Mar 2023
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Glycogen Storage Disease Type IIPhase 3
JP
04 Dec 2018
Glycogen Storage Disease Type IIPhase 3
BA
04 Dec 2018
Glycogen Storage Disease Type IIPhase 3
NZ
04 Dec 2018
Glycogen Storage Disease Type IIPhase 3
KR
04 Dec 2018
Glycogen Storage Disease Type IIPhase 3
CA
04 Dec 2018
Glycogen Storage Disease Type IIPhase 3
AU
04 Dec 2018
Glycogen Storage Disease Type IIPhase 3
AR
04 Dec 2018
Glycogen Storage Disease Type IIPhase 3
GB
04 Dec 2018
Glycogen Storage Disease Type IIPhase 3
TW
04 Dec 2018
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
125
(Cipaglucosidase Alfa/Miglustat)
uiycnntwcr(jqfgycmvij) = hwiyofydls fcfotviaxy (niczxlyjwo, mjmepfmxem - yykpsqphis)
-
11 Sep 2023
Placebo
(Alglucosidase Alfa/Placebo)
uiycnntwcr(jqfgycmvij) = fdgczixpem fcfotviaxy (niczxlyjwo, eaqijwrpjs - aompqcwnaj)
Phase 1/2
Glycogen Storage Disease Type II
Creatine kinase | Urine glucose tetrasaccharide
23
(taeisvagck) = umkjfpnrop sxfkiomuzy (bcvjdrbxwo, 49.62)
Positive
19 Mar 2023
(taeisvagck) = fneyqwcxbu sxfkiomuzy (bcvjdrbxwo, 29.96)
Phase 3
119
alglucosidase alfa+placebo+cipaglucosidase alfa+miglustat
(grpuoctqns) = htwmtjruod sznawzowdn (zvhzvdykzy )
Positive
19 Mar 2023
(grpuoctqns) = quuqpsoyju sznawzowdn (zvhzvdykzy )
Phase 1/2
23
(ERT experienced:Cohort 1+Cohort 4)
(aydimoztnk) = whkcofszek fmnxklnkxz (wljsrnmgxz )
Positive
22 Sep 2022
(ERT naïve:Cohort 3)
(aydimoztnk) = fjylasihmr fmnxklnkxz (wljsrnmgxz )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free